Phase I dose-escalation trial of tremelimumab in combination with bicalutamide in patients with recurrent prostate cancer. Background: Although 45% of mCRPC patients (pts) achieve prostatic-specific ...
(ECF No. 14.) 1 Plaintiff’s counsel withdrew on October 20, 2011, (ECF No. 22), and Plaintiff went forward pro se. Throughout 2012 Plaintiff failed to appear at several scheduled conferences and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback